Altagracia M, Monroy-Noyola A, Osorio-Rico L, Kravzov J, Alvarado-Calvillo R, Manjarrez-Marmolejo J, Ríos C
Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, Mexico DF, Mexico.
Neurosci Lett. 1994 Jul 18;176(1):52-4. doi: 10.1016/0304-3940(94)90869-9.
We tested the ability of dapsone (4,4'-diamino-diphenyl sulfone) to attenuate kainic acid-induced seizures. We observed that 9.375 and 12.5 mg/kg doses of dapsone administered 30 min before a single kainic acid (10 mg/kg) i.p. injection were able to decrease the time of electroencephalographic seizures by 52% and 82%, respectively, as compared with rats administered with 10 mg/kg kainic acid only. The 12.5 mg/kg dose of dapsone was also able to diminish both kainic acid-evoked body and head shakes (58%) and kainic acid-induced mortality (75%). These results suggest that dapsone could be used in clinical trials as anticonvulsant.
我们测试了氨苯砜（4,4'-二氨基二苯砜）减轻红藻氨酸诱导的癫痫发作的能力。我们观察到，在单次腹腔注射10mg/kg红藻氨酸前30分钟给予9.375mg/kg和12.5mg/kg剂量的氨苯砜，与仅给予10mg/kg红藻氨酸的大鼠相比，脑电图癫痫发作时间分别减少了52%和82%。12.5mg/kg剂量的氨苯砜还能够减少红藻氨酸诱发的身体和头部震颤（58%）以及红藻氨酸诱导的死亡率（75%）。这些结果表明氨苯砜可用于临床试验作为抗惊厥药。
